Q2 2025 Management View Steven O. Vondran, President and CEO, stated that "2025 continues to be a good year." He highlighted ...

Novo Nordisk's stock has dropped 21% after the company lowered its sales forecast and named Mike Doustdar as the new CEO.

Shipowners grapple with OPEC+ supply increases, tensions in the Middle East, and rising numbers of newbuildings.

The International Monetary Fund raised its outlook for economic growth across emerging market and developing economies this ...

Schneider adds that investors seem optimistic about American Tower due to stronger domestic organic growth heading into ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

Q2 2025 Management View CEO Zvi Alon stated that Tigo achieved its "sixth increase in sequential quarterly revenue growth, growing 27.7% sequentially and 89.4% on a year-over-year basis." He reported ...

Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's ...

American Tower (AMT) stock dipped 2.3% in Tuesday premarket trading after REIT's 2025 AFFO guidance midpoint was ...

The IMF on Tuesday raised its global growth forecasts for 2025 and 2026 slightly, citing stronger-than-expected purchases ...

Discover AtriCure's standout Q2 2025 performance with 17% revenue growth, boosted by product innovation and international expansion.

The International Monetary Fund has revised India’s economic growth forecast upwards to 6.4% for both 2025 and 2026, citing a ...